Affinity Asset Advisors
Overview
Affinity Asset Advisors is a hedge fund manager founded in 2017 that pursues a long-short equity strategy focused on the healthcare sector, particularly pharmaceutical and biotechnology companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Odyssey Therapeutics | Sep 2025 | Series D | Co-investor |
| LEXEO Therapeutics | May 2025 | Private Placement | Co-investor |
| Climb Bio, Inc. | Apr 2026 | Private Placement | Co-investor |
| Jasper Therapeutics | Jul 2026 | PIPE | Lead |
| TRexBio | Jan 2026 | Series B Extension | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Affinity Asset Advisors based?
Affinity Asset Advisors is headquartered in New York City, New York, United States.
When was Affinity Asset Advisors founded?
Affinity Asset Advisors was founded in 2017.
How many portfolio companies does Affinity Asset Advisors have?
Affinity Asset Advisors has 7 portfolio companies in Caplight's dataset.
What are some companies in Affinity Asset Advisors's portfolio?
Portfolio companies visible on Caplight include Odyssey Therapeutics, LEXEO Therapeutics, Climb Bio, Inc., Jasper Therapeutics, TRexBio.
What was Affinity Asset Advisors's most recent investment shown here?
Affinity Asset Advisors's most recent investment in this portfolio sample was in Jasper Therapeutics in 2026.
What sectors does Affinity Asset Advisors focus on?
Affinity Asset Advisors focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Affinity Asset Advisors focus on?
Affinity Asset Advisors typically invests at the MultiStage stage.
What is Affinity Asset Advisors's AUM?
Affinity Asset Advisors's assets under management are estimated between $807.9M and $807.9M.